Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 109.47$. Average daily volumn in 3 months 1.51M. Market cap 251.38B



Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 110.88$. Total volume : 510.70k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)
Last Price
110.88$
Change
-0.55
Volume
510.70k

Previous Close111.43
Open109.73
Day Range108.71-110.88
Bid110.43 x 900
Ask110.48 x 900
Volume510.7k
Average Volume1.51M
Market Cap251.38B
Beta0.24
52 Week Range83.86-122.16
Trailing P/E36.47
Foward P/E28.14
Dividend (Yield %)1.41%
Ex-Dividend Date2022-03-25



Financial Details


According to Novo Nordisk A/S's financial reports the company's revenue in 2021 were 140.8B an increase( +11.11%) over the years 2020 revenue that were of 126.95B. In 2021 the company's total earnings were 47.76B while total earnings in 2020 were 42.14B( +11.9%).


Loading ...



Organization

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Market Cap:
251.38B
Revenue:
140.8B
Total Assets:
194.51B
Total Cash:
10.72B


News about "Novo Nordisk A/S"

spire-wealth-management-reduces-stock-position-in-novo-nordisk-as-nysenvo-image

Spire Wealth Management Reduces Stock Position in Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 15 hours ago

Spire Wealth Management lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) by 23.2% in the first quarter, Holdings Channel.com reports. The fund owned 5,669 shares of the ...See details»


advisornet-financial-inc-boosts-position-in-novo-nordisk-as-nysenvo-image

AdvisorNet Financial Inc Boosts Position in Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 15 hours ago

AdvisorNet Financial Inc increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) by 51.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 1,679 shares of the ...See details»


Novo Nordisk A/Sโ€™s Stock Price Soared Recently, But There Might Be Trouble Ahead

Source from : stocksregister - 4 days ago

Novo Nordisk A/S (NYSE:NVO) traded at $109.28 at last check on Tuesday, June 28, made a downward move of -3.20% on its previous dayโ€™s price. Looking at the stock we see that its previous close was ...See details»


novo-nordisk-as-share-repurchase-programme-image

Novo Nordisk A/S โ€“ Share repurchase programme

Source from : Yahoo Finance - 4 days ago

Bagsvรฆrd, Denmark, 27 June 2022 โ€“ On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...See details»


Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today

Source from : Benzinga.com - 1 days ago

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market ...See details»


Novo Nordisk A/S (NYSE:NVO) Upgraded to Neutral by BNP Paribas

Source from : ETF Daily News - 3 days ago

BNP Paribas upgraded shares of Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) from an underperform rating to a neutral rating in a research note issued to investors on Monday, MarketBeat reports.See details»


Flagship Harbor Advisors LLC Has $381,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Source from : ETF Daily News - 4 days ago

Flagship Harbor Advisors LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) by 2.8% in the first quarter, according to its most recent disclosure with the SEC.See details»


Novo Nordisk A/S Class B - Stock Quote NOVOB

Source from : Morningstar%2c Inc. - 9 days ago

As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information ...See details»


hololens-2-helps-novo-nordisk-employees-see-work-in-new-ways-image

HoloLens 2 helps Novo Nordisk employees see work in new ways

Source from : Microsoft - 4 days ago

Oliver Brask Pedersen figured his first day at work as a technician at Novo Nordisk would follow many of the familiar patterns โ€“ get introduced to new people, find out where the cafeteria is located ...See details»


Will investors benefit from quality and momentum at Novo Nordisk A/S?

Source from : Yahoo Finance - 9 days ago

The Novo Nordisk A/S (CPH:NOVO B) share price is currently trading at DKK761.9. But to predict what the price will look like in the next 12 months and beyond, ...See details»


echosens-and-novo-nordisk-announce-partnership-to-increase-awareness-and-advance-early-diagnosis-of-nash-image

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

Source from : YAHOO!Finance - 9 days ago

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of ...See details»


Novo Nordisk announces innovation plans in rare blood disordersโ€™ treatment

Source from : The Financial Express - 2 days ago

Novo Nordisk will be sharing its new data in the treatment of rare ... concizumab prophylaxis versus on-demand therapies will also be presented. BioMarinโ€™s hemophilia gene therapy Roctavian gets ...See details»


Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA

Source from : Nasdaq - 9 hours ago

Shares of Sanofi SNY were down 5% on Jun 30 after management announced that the FDA has placed a partial clinical hold on the companyโ€™s phase III studies, evaluating its investigational Brutonโ€™s ...See details»


3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock

Source from : Yahoo Finance - 14 days ago

While the historical EPS growth rate for Novo Nordisk is 7.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 6.7% this year, crushing the industry ...See details»